1. ALLA AKTIER
  2. NYHETER
  3. CANTARGIA

Cantargia

Nyheter Cantargia Nyheter alla bolag

Invitation to presentation of Cantargia’s interim report January – September 2024

Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) invites investors, analysts and the press to a presentation of the interim report for January – September 2024 at 3 pm (CET) on November 15, 2024. The report will be published at 07:00 am (CET) the same day.

In conjunction to the report, Cantargia invites investors, analysts, and media to an audiocast with teleconference (in English) on November 15, at 3:00 pm (CET), where Cantargia’s CEO, Göran Forsberg, and CFO, Patrik Renblad, will present Cantargia and comment on the report, followed by a Q&A-session.

If you wish to participate via webcast, please use the link below. Via the webcast you will be able to ask written questions. Webcast: https://ir.financialhearings.com/cantargia-q3-report-2024.

If you wish to participate via teleconference, please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference: https://conference.financialhearings.com/teleconference/?id=50048870.

The webcast will also be available on demand on Cantargia’s corporate website: www.cantargia.com

For further information, please contact
Göran Forsberg, CEO
Telephone: +46 (0)46-275 62 60
E-mail: goran.forsberg@cantargia.com

About Cantargia
Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. Cantargia’s oncology program, the antibody nadunolimab (CAN04), is being studied clinically, primarily in combination with chemotherapy with a focus on pancreatic cancer, non-small cell lung cancer and triple-negative breast cancer. Positive data for the combinations indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia’s second development program, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on hidradenitis suppurativa and systemic sclerosis.
 
Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at www.cantargia.com.

Attachments
Invitation to presentation of Cantargia’s interim report January – September 2024

Datum 2024-11-01, kl 10:00
Källa MFN
Bifogade filer
Invitation to presentation of Cantargia’s interim report January – September 2024
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 15 000 unika besökare per månad. Vår discord har över 6000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!